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Human blood groups were discovered over 100 years ago.
During the course of the 20th century, a variety of different styles
of terminology has been used to denote them. The Inter-
national Society of Blood Transfusion (ISBT) established a
Working Party in 1980 to devise a genetically based numerical
terminology for red cell surface antigens. In 1990, the Work-
ing Party published a monograph describing a numerical
terminology for 242 red cell antigens [1]. Another mono-
graph listing 254 antigens was published in 1995 [2] and four
brief updates have followed [3–6]. In the 9 years since the
1995 report, many amendments to the classification have
been necessary: 30 new antigens have been identified and six
new systems created. Since 1995, the genes for nine blood
group systems have been identified, so that sequenced genes
for all 29 systems are now available. All blood group system
genes have been located on a specific region of a chromo-
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The purpose of this monograph is to describe the ISBT
terminology for red cell surface antigens and to tabulate the
complete current version of the classification. Much of the
information provided in the 1995 monograph [1] is reiterated
here so that referral back will not generally be required, but
only references published after 1995 are provided.
 
The ISBT numerical terminology
 
The mandate of the Committee is to provide a numerical
terminology for red cell surface antigens. By definition, these
antigens must be defined serologically by the use of a specific
antibody. Numerical designations and blood group symbols
cannot be allocated to nucleotide or amino acid sequences or
polymorphisms, even though the presence of specific blood
group antigens may be indicated by these techniques. All
antigens receiving ISBT numbers must have been shown to
be inherited characters.
All authenticated antigens fall into one of four classifica-
tions: systems; collections; low-incidence antigens (700 series);
and high-incidence antigens (901 series). A blood group system
consists of one or more antigens controlled at a single gene
locus, or by two or more very closely linked homologous
genes with little or no observable recombination between
them. Each system has been shown to be genetically discrete
from every other system. Collections consist of serologically,
biochemically, or genetically related antigens, which do not
fit the criteria required for system status. The 700 and 901
series contain low- and high-incidence antigens, respectively,
which cannot be included in a system or collection.
Each antigen belonging to a blood group system is identi-
fied by a six-digit number (Tables 1–3). The first three digits
represent the system (e.g. 006 for Kell) and the second three




). Alternatively, the system
symbol followed by the antigen number may be used
(e.g. KEL003 or, more usually, KEL3 as sinistral zeros may be







location CD numbers Refs
001 ABO ABO ABO 9q34.2
002 MNS MNS GYPA, GYPB, GYPE 4q31.21 CD235
003 P P1 22q11.2–qter
004 Rh RH RHD, RHCE 1p36.11 CD240
005 Lutheran LU LU 19q13.32 CD239
006 Kell KEL KEL 7q34 CD238
007 Lewis LE FUT3 19p13.3
008 Duffy FY FY 1q23.2 CD234
009 Kidd JK SLC14A1 18q12.3 [7,8]
010 Diego DI SLC4A1 17q21.31 CD233
011 Yt YT ACHE 7q22.1
012 Xg XG XG, MIC2 Xp22.33, Yp11.3 CD99b
013 Scianna SC ERMAP 1p34.2 [9]
014 Dombrock DO DO 12p12.3 [10,11]
015 Colton CO AQP1 7p14.3
016 Landsteiner-Wiener LW ICAM4 19p13.2 CD242
017 Chido/Rodgers CH/RG C4A, C4B 6p21.3
018 H H FUT1 19q13.33 CD173
019 Kx XK XK Xp21.1
020 Gerbich GE GYPC 2q14.3 CD236
021 Cromer CROM DAF 1q32.2 CD55
022 Knops KN CR1 1q32.2 CD35
023 Indian IN CD44 11p13 CD44
024 Ok OK BSG 19p13.3 CD147 [12]
025 Raph RAPH CD151 11p15.5 CD151 [13–15]
026 John Milton Hagen JMH SEMA7A 15q24.1 CD108 [16,17]
027 I I GCNT2 6p24.2 [18,19]
028 Globoside GLOB B3GALT3 3q26.1 [20,21]
029 Gill GIL AQP3 9p13.3 [22,23]




















removed). Phenotypes are represented by the system symbol,
followed by a colon, followed by a list of antigens separated
by commas. Those antigens shown to be absent are preceded








3,4). Genes are designated by
the system symbol, followed by an asterisk, followed by the








). Genotypes have the system
symbol, followed by an asterisk, followed by alleles or






























and genotype designations are italicized (or underlined).
Antigen, phenotype, gene and genotype designations for
collections are constructed in the same way. For the 700 and
901 series, 700 or 901 replaces the system symbol.
 
Symbols for gene loci
 
The symbol for a gene or cluster of genes controlling a blood





the gene controlling the Colton system). The genes control-
ling all of the blood group systems have been cloned and, in
many cases, the gene locus has an alternative symbol (Table 1),
usually because the protein product of the gene is of known
function or the gene had an existing symbol before the asso-
ciation with the blood group was known. Examples: the genes
controlling expression of the Diego and Kidd antigens encode























, respectively, the genes produc-
ing the water transporters Aquaporin-1 and -3; the presence









; and the presence of Lewis





























, are involved in the expression of antigens
of the MNS system. The symbol for the gene governing a
serologically determined blood group antigen comprises
























). When the gene encoding a blood group antigen is
determined by non-serological means, such as nucleotide




 instead of JK, and DAF instead of CROM ) and allele
designations should conform to the established terminologies
employed for nucleotide polymorphisms (see refs 24,25 and
www.bioc.aecom.yu.edu/bgmut/index.htm).
It is important to remember that when symbols such as
RH*2 or MNS*10 are used, the symbol does not necessarily
represent a single defined gene, but one of a cluster of genes
or a hybrid of two genes.
A ‘popular’, alternative terminology
The numerical terminology was devised primarily for com-
puter storage of information on blood group antigens and to
provide a framework for a genetical classification. The numerical
terminology is not suitable for everyday communication and
many scientists working in the field of human blood groups
prefer not to use it in publications. This has led to a variety
of alternative names being used for some blood group anti-
gens. In an attempt to introduce some uniformity, a recom-
mended list of alternative names for antigens is provided in
Table 3. In most cases, the name or symbol is identical to that
originally published, but in a few cases the more commonly
used name is provided. In addition, there are recommended
formats for describing phenotypes in the alternative termi-
nology. These mostly employ traditional terminology, and
examples are shown in Table 4. A more complete list has been
published previously [4].
Blood group systems
There are currently 29 systems containing a total of 245
antigens (Tables 1 and 3).
Modifications since 1995: existing systems
002, the MNS system
Five new antigens have been added. Absence of the high-
incidence antigen MNS39 (ENEP) and presence of the low-
incidence antigen MNS41 (HAG) is associated with an Ala65Pro
substitution in glycophorin A (GPA) [26]. The absence of
MNS42 (ENAV, previously AVIS) and the presence of MNS43
(MARS), its low-incidence antithetical antigen, results from
a Gln63Lys substitution in GPA [27]. Both of these substitu-
tions are associated with abnormal expression of DI4 (Wrb).
MNS40 (ENEH) is absent from glycophorin A of the pheno-
type GP.Vw (Mi.I); the glycophorin A has a Thr28Met sub-
stitution and expresses MNS9 (Vw) antigen [28].
003, the P system
Evidence was presented suggesting that the same transferase
encoded by A4GALT, is responsible for the biosynthesis of
Table 2 Examples of antigen, phenotype, gene, and genotype designations 







Antigen LU1 or 005001 Lua
Phenotype LU:−1,2 Lu(a–b+)
Gene LU *1 Lua













001 002 003 004 005 006 007 008 009 010 011 012 013 014 015 016 017 018 019 020 021 022 023 024
001 ABO A B A,B A1 …
002 MNS M N S s U He Mia Mc Vw Mur Mg Vr Me Mta Sta Ria Cla Nya Hut Hil Mv Far sD Mit
003 P P1 … …
004 RH D C E c e f Ce Cw Cx V Ew G … … … … Hro Hr hr
S VS CG CE Dw …
005 LU Lua Lub Lu3 Lu4 Lu5 Lu6 Lu7 Lu8 Lu9 … Lu11 Lu12 Lu13 Lu14 … Lu16 Lu17 Aua Aub Lu20 Lu21
006 KEL K k Kpa Kpb Ku Jsa Jsb … … Ula K11 K12 K13 K14 … K16 K17 K18 K19 Km Kpc K22 K23 K24
007 LE Lea Leb Leab LebH ALeb BLeb
008 FY Fya Fyb Fy3 Fy4 Fy5 Fy6
009 JK Jka Jkb Jk3
010 DI Dia Dib Wra Wrb Wda Rba WARR ELO Wu Bpa Moa Hga Vga Swa BOW NFLD Jna KREP Tra* Fra SW1
011 YT Yta Ytb
012 XG Xga CD99
013 SC Sc1 Sc2 Sc3 Rd STAR
014 DO Doa Dob Gya Hy Joa
015 CO Coa Cob Co3
016 LW … … … … LWa LWab LWb
017 CH/RG Ch1 Ch2 Ch3 Ch4 Ch5 Ch6 WH Rg1 Rg2
018 H H
019 XK Kx
020 GE … Ge2 Ge3 Ge4 Wb Lsa Ana Dha GEIS
021 CROM Cra Tca Tcb Tcc Dra Esa IFC WESa WESb UMC GUTI SERF ZENA
022 KN Kna Knb McCa Sl1 Yka McCb Sl2 Sl3*







025 026 027 028 029 030 031 032 033 034 035 036 037 038 039 040 041 042 043 044 045 046
002 MNS Dantu Hop Nob Ena EnaKT ‘N’ Or DANE TSEN MINY MUT SAT ERIK Osa ENEP ENEH HAG ENAV MARS
004 RH … c-like cE hrH Rh29 Goa hrB Rh32 Rh33 HrB Rh35 Bea Evans … Rh39 Tar Rh41 Rh42 Crawford Nou Riv Sec
006 KEL VLAN TOU RAZ VONG
047 048 049 050 051 052 053 054 055 056
004 RH Dav JAL STEM FPTT MAR BARC JAHK DAK LOCR CENR
… = obsolete (see Table 9); *provisional.
308 G. L. Daniels et al.
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both P1 and Pk (209002 of the GLOB Collection) [29]. How-
ever, because of reports of conflicting evidence [30] (L. Tilley,
G. Daniels, unpublished) Pk has not joined the P system.
004, the Rh system
Five antigens of low incidence have been added: RH52 (BARC)
is produced by most DVICe haplotypes, but is not produced by
DVIcE haplotypes [31]; RH53 (JAHK) is associated with the
rare Rh phenotype rG [32]; RH54 (DAK) with DIIIa, DOL, and
some other rare Rh phenotypes [33]; RH55 (LOCR, previously
700053) with weak expression of RH4 (c) and RH5 (e) [34]; and
RH56 (CENR) with an RHCE-D hybrid gene associated with
RH8 (Cw) and altered expression of RH2 (C) and RH5 (e) [35].
A new terminology has been devised for epitopes of RH1
(D) [36]. Basically, each epitope has two numbers, one repre-
senting the conventional epD1 to epD9 system proposed by
Lomas et al. [37], the other representing subdivisions of those
numbers. The complete numerical terminology for epD1 is
004001.001.001 (abbreviated to epD1.1) and the epD1 subsplit
caused by DFR is 004001.001.002 (epD1.2). Partial D antigens
will be designated by up to four upper case letters or Roman
numerals on the line; for example DIIIa, DIV, DHAR, DFR.
005, the Lutheran system
Absence of a new Lutheran antigen of high incidence, LU21,
is associated with homozygosity for an LU mutation encoding
Asp94Glu [38].
006, the Kell system
KEL25 (VLAN) and KEL28 (VONG) are low-incidence antigens
associated with Arg248Gln and Arg248Trp, respectively, in
the Kell glycoprotein [39,40]. KEL26 (TOU) and KEL27 (RAZ)
Table 4 Examples of the format recommended for phenotype designation in the alternative, ‘popular’ terminology
 
 




MNS:1,2,−3,4,5,−6,7 M+ N+ S– s+ U+ He– Mi(a+) (in ISBT order)
Symbols such as Mi.III or GP.Mur, En(a–), Mk are also acceptable
P:1 P1+ or P1
P:−1 P1– or P2 (if shown to be GLOB:1)
RH:1,2,−3,4,5,−8,32,33,−36 D+ C+ E– c+ e+ Cw– Rh:−32,33 Be(a–) (in ISBT order)
The order D C c E e would be an acceptable alternative. Probable genotypes as
phenotypes (e.g. R1R2 or DCe/DcE; R1r C
w+ or DCe/dce Cw+) are acceptable, providing
it is made clear that they are only probable genotypes based on haplotype frequencies.
Null and mod phenotypes: Rhnull; Rhmod.
LU:−1,2,3,4 Lu(a–b+) Lu:3,4.
Null phenotype: Lunull or Lu(a–b–)
KEL:−1,2,−3,4,5,−6,7,11,12,13,−17,−21 K– k+ Kp(a–b+c–) Ku+ Js(a–b+) K:11,12,13,−17,−21
Null and mod phenotypes: Ko or Kellnull; Kmod.
FY:1,2,3 Fy(a+b+) Fy:3
FY:−1,−2,−3 Fy(a–b–) Fy:−3
Fyx may be used as a phenotype
DI:1,2,−3,4,−5,−6,−7 Di(a+b+) Wr(a–b+) Wd(a–) Rb(a–) WARR–
DO:1,2,3,4,5 Do(a+b+) Gy(a+) Hy+ Jo(a+)
LW:5,6,−7 LW(a+b–) LW(ab+)
CH/RG:1,2,−7,11,12 Ch:1,2 WH– Rg:1,2
H:−1 H – The symbol Oh may be used for the true Bombay phenotype (red cells totally
H-deficient, ABH non-secretors). Otherwise the terms ‘Red cell H-deficient
secretor’ and ‘Red cell H-deficient non-secretor’ are recommended.
XK:−1 Kx– or McLeod
GE:2,3,4,−5,−6,−7,−8,−9 Ge:2,3,4 Wb– Ls(a–) An(a–) Dh(a–) GEIS–
GE:−2,−3,4 Ge:−2,−3,4 or Gerbich phenotype
GE:−2,3,4 Ge:−2,3,4 or Yus phenotype
GE:−2,−3,−4 Ge:−2,−3,−4 or Leach phenotype
RAPH:1 MER2+
I:1 I adult
I:−1 i adult or cord
© 2004 Blackwell Publishing Ltd. Vox Sanguinis (2004) 87, 304–316
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are antigens of high incidence, absent from the Kell glycoprotein
with Arg406Gln [41] and Glu299Lys [39] substitutions,
respectively.
007, the Lewis system
Three antigens, previously known for many years, were
added to this system. LE4 (LebH) is defined by antibodies that
react with LE:2 [Le(b+)] cells, but only when H1 (H) is strongly
expressed (group O and A2 phenotypes). LE5 (ALe
b) and LE6
(BLeb) are expressed when A type 1 and B type 1 are modified
by the product of the Lewis gene, FUT3 [42].
010, the Diego system
Seventeen new antigens have been added, all of low incid-
ence and all associated with mutations in SLC4A1 encoding
amino acid substitutions in the erythrocyte anion exchanger
(Table 5). The DI19 designation for Tra is still provisional
because only one case was analysed.
012, the Xg system
CD99, a glycoprotein encoded by a gene on both X and Y
chromosomes, is recognized by monoclonal antibodies and
human alloantibodies [54,55]. MIC2, the structural gene for
CD99, is closely linked to XG and shares substantial sequence
homology with XG. Consequently, CD99 became XG2.
013, the Scianna system
Following the discovery that the Scianna antigens are
expressed by the red cell adhesion protein, human ERMAP,
expression of the low-incidence antigen, 700015 (Rd), was
found to be associated with a mutation in ERMAP encoding
Pro60Ala [9]. 700015 has become SC4. A new antigen of high
incidence, STAR, is associated with Glu47Lys in ERMAP [56]
and numbered SC5.
018, the Hh system
The system name has been changed to H.
020, the Gerbich system
A new antigen of low incidence, GEIS, associated with Thr32Asn
in GPC and Thr11Asn in GPD [57], has been numbered GE9.
021, the Cromer system
Three new antigens of high incidence have been added:
CROM11 (GUTI) [58], CROM12 (SERF) [59], and CROM13
(ZENA) [60] are associated with Arg206His, Pro182Leu and
His208Gln in CD55, respectively.
022, the Knops system
Three new antigens have been added: KN6 to KN8. KN6
(McCb) represents Lys1590Glu in CD35, which is also associ-
ated with the absence of KN3 (McCa) [61]. KN4 (previously
Sla, now Sl1) requires Arg1601 on CD35, KN7 (previously Vil,
now Sl2) requires Gly1601, and KN8 (Sl3) requires both
Arg1601 and Ser1610 [61,62]. The number KN8 is provisional
because further complications are predicted.
Modifications since 1995: new systems
024, the Ok system
The high-incidence antigen OK1 (Oka, previously 901006)
became the sole antigen of the Ok system following identifi-
cation of the gene (BSG) encoding the protein and of the
amino acid substitution (Glu92Lys) responsible for the
OK:−1 phenotype [12].
025, the Raph system
This new system contains one antigen: RAPH1 (MER2, pre-
viously 901011). Distinction of RAPH from the other blood
group systems was demonstrated by family studies and by
the positioning of CD151, the controlling gene, at 11p15.5
[13–15].
026, the John Milton Hagen system
JMH1 (JMH, previously 901007) is carried on the semaphorin
CD108 [16]. The gene encoding CD108, SEMA7A, is located
on the long arm of chromosome 15 [17], which distinguishes
JMH1 from all existing blood group systems. JMH1 represents
the antigen detected by antibodies produced by JMH:−1
individuals.
027, the I system
GCNT2, the gene encoding the N-acetylglucosaminyltrans-
ferase responsible for converting i-active straight chains to








DI5 Wda 700030 Val557Met [43,44]
DI6 Rba 700027 Pro548Leu [44]
DI7 WARR 700055 Thr552Ile [45]
DI8 ELO 700051 Arg432Trp [46,47]
DI9 Wu 700013 Gly565Ala [48]
DI10 Bpa 700010 Asn569Lys [47]
DI11 Moa 700022 Arg656His [47]
DI12 Hga 700034 Arg656Cys [47]
DI13 Vga 700029 Tyr555His [47]
DI14 Swa 700004 Arg646Gln or Trp [49]
DI15 BOW 700046 Pro561Ser [47,50,51]
DI16 NFLD 700037 Glu429Asp, Pro561Ala [51]
DI17 Jna 700014 Pro566Ser [52]
DI18 KREP Pro566Ala [50]
DI19 Tra* 700008 Lys551Asn [44]
DI20 Fra 700026 Glu480Lys [53]
DI21 SW1 700041 Arg646Trp [49]
310 G. L. Daniels et al.
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I-active branched chains, has been cloned and some muta-
tions responsible for the i adult phenotype identified [18,19].
I1 antigen (I, previously 207001) is the only antigen of the I
system. The i antigen, the precursor of I1, provisionally remains
as 207002.
028, the Globoside system
The gene (B3GALT3) encoding the N-acetylgalactosaminyl-
transferase (globoside synthase) responsible for converting
Pk (209002) to P (previously 209001, globoside) has been
cloned and inactivating mutations responsible for the Pk (P-
negative) phenotype have been identified [20,21]. P has
become GLOB1, the only antigen of the Globoside system.
029, the GIL system
GIL1, the only antigen of the GIL system, is an antigen of high
incidence located on the glycerol transporter aquaporin 3,
and the GIL:−1 phenotype results from an inactivating muta-
tion within the AQP3 gene [22,23]. AQP3 is on chromosome
9p13, so GIL is genetically discrete from all other blood group
systems.
Guidelines for the establishment of new blood 
group systems
For an antigen to form a new blood group system it must be
defined by a human alloantibody, be an inherited character, the
gene encoding it must have been identified and sequenced,
and its chromosomal location must be known. In addition, the
gene must be different from, and not a closely linked homo-
logue of, all other genes encoding antigens of existing blood
group systems.
All established blood group systems meet these criteria.
Guidelines for the inclusion of a new specificity 
in an established system
All antigens awarded an ISBT number must have been shown
to be inherited, and at least one of the following four criteria
must be met.
(1) An antithetical relationship between a new antigen and
one already assigned to the system.
(2) Demonstration that expression of the antigen is associ-
ated with a variation in the nucleotide sequence of the gene
controlling the system.
(3) Evidence, from a linkage analysis of family data,
that the controlling allele is probably a newly recognized form
of the pertinent gene, and supporting serological or bio-
chemical information.
(4) Demonstration that an antigen is located on a protein
or glycoprotein that carries other antigens belonging to the
system. It must be remembered, however, that this could
result from post-translational modification of a gene
product, such as glycosylation, which would not support
inclusion within the system.
Blood group collections
There are six blood group collections (Table 6).
A new Collection, 211 or Vel, was created to include two
serologically related antigens of high incidence, Vel (VEL1,
previously 901001) and ABTI (VEL2, previously 901015)
[63,64].
An antibody produced by a patient with ER:−1,−2 red cells
and with the characteristics of antibodies of the ER Collection
reacted with ER:1,−2, ER:−1,2, and the only other example
of ER:−1,−2 red cells [65]. The antigen recognized by this
antibody has become ER3 (208003) of the ER Collection.
Since 1995, 207001 (I1, I) has formed the I system and
retains the symbol I1, and 209001 (GLOB1, P) has formed the
Globoside system and retains the symbol GLOB1. The creation
of the I and Globoside systems means that these two systems
have identical symbols, I and GLOB, to those of Collections
207 and 209. This should not cause confusion, however,
as I1 and GLOB1 cannot refer to 207001 and 209001, as those
numbers are now obsolete. Collection 207 now contains only
one antigen. These anomalies will be resolved when a separate
carbohydrate collection is created.
700 series, low-incidence antigens
There are currently 19 antigens in the 700 series (Table 7).
Since 1995, no new numbers have been added and 18 numbers
have been made obsolete: 16 antigens have joined the Diego




No. Name Symbol No. Symbol
Incidence 
percentage






207 Ii I 207002 i *



























*By standard serological tests, may appear to be low incidence. Obsolete 
collections: 201 Gerbich; 202 Cromer; 203 Indian; 204 Auberger; 
206 Gregory; 211 Wright.
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system (Table 5); 700015 (Rd) has become SC4; and 700053
(LOCR) has become RH55.
Criteria for inclusion in the 700 series:
(1) An incidence of < 1% in most populations tested.
(2) Distinction from all other numbered low-incidence
antigens of the 700 series as well as those of the blood group
systems and collections.
(3) Demonstration of inheritance through at least two
generations.
901 series, high-incidence antigens
There are currently nine antigens in the 901 series (Table 8).
Since 1995, two new antigens, both of high incidence, have
been added: 901015 (ABTI) [63] and 901016 (MAM) [66],
although 901015 (ABTI) has now become VEL2 of the 211 col-
lection. Three antigens became the sole antigens of new blood
group systems and their 901 numbers are obsolete: 901006
(Oka) has become OK1; 901007 (JMH) has become JMH1; and
901011 (MER2) has become RAPH1 (Table 1).
The gene encoding the β1,4-N-acetylgalactosaminyltrans-
ferase responsible for 901012 (Sda) antigen has been cloned
[67,68], but 901012 has not formed a new blood group system
because the molecular basis for the Sda polymorphism has not
been determined.
Criteria for inclusion in the 901 series:
(1) An incidence of > 90% in most populations tested.
(2) Distinction from all other numbered high-incidence
specificities.
(3) Demonstration that the antigen is lacking from the red
cells of at least 2 sibs, i.e. that the negative phenotype is
genetically determined.
Obsolete numbers
There is no recycling of blood group numbers: once a number
has been allocated to a specificity, that number cannot be
subsequently used for any other specificity. Consequently, if
the number of a specificity becomes inappropriate, then that
number becomes obsolete. Obsolete numbers are listed in
Table 9.
Procurement of ISBT numerical designations
Choice of symbol
Symbols for designations of new specificities will consist of
three to six on-line capital letters and must not duplicate,
alphabetically or phonetically, any current or obsolete sym-
bols shown in the tables. Also, symbols used in related fields,
such as those used for platelet and leucocyte antigens, must
be avoided. Symbols for specificities that may herald new
blood group systems, and thus new genes, have the further
constraint that they must differ from any symbols given to
genes by the HUGO Nomenclature Committee (http://www.
gene.ucl.ac.uk/nomenclature/).
Procedures for acquisition of an ISBT number
The initial stipulation is that materials for defining the new
specificity should be available for either circulation or in-
house testing; the futility of defining a new specificity from
which future new specificities cannot be distinguished is
obvious. Proposals should be submitted with supporting
data to the members of the Committee listed below, who are
authorized to allocate numbers provisionally in consultation
with the Chair. All decisions must be ratified by the Committee
before being finalized.
• For a new blood group system or collection: Dr Geoff Daniels.
• For a specificity number within an established system: Dr
Marion Reid for the MNS system; Dr Sylvano Wendel or
Mrs Marilyn Moulds for the Rh system; Dr Jan Jørgensen
for other systems.
• For a specificity number in a current collection: Dr Geoff
Daniels.
• For a 700 number: Dr Teresa Zelinski.
• For a 901 number: Dr Geoff Daniels.
Table 7 The700 series: low-incidence antigens
 
 
No. Name Symbol No. Name Symbol
700002 Batty By 700040 Rasmussen RASM
700003 Christiansen Chra 700043 Oldeide Ola
700005 Biles Bi 700044 JFV
700006 Box Bxa 700045 Katagiri kg
700017 Torkildsen Toa 700047 Jones JONES
700018 Peters Pta 700049 HJK
700019 Reid Rea 700050 HOFM
700021 Jensen Jea 700052 SARA
700028 Livesay Lia 700054 REIT
700039 Milne
Table 8 The 901 series: high-incidence antigens
 
 
No. Name Symbol No. Name Symbol
901002 Langereis Lan 901012 Sid Sda
901003 August Ata 901013 Duclos
901005 Jra 901014 PEL
901008 Emm 901016 MAM
901009 Anton AnWj
312 G. L. Daniels et al.
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Conclusions
Although the primary function of the Committee is to
monitor and update the terminology, there are two main
issues that need to be tackled in the future: updating and
redefining the terminology for blood group genes and alleles;
and devising a collection for those carbohydrate antigens
that do not belong to a system.
The Committee strongly urges that all authors in the field
of human red cell blood groups should use the terminology
provided in Tables 1–8 in either the alphabetical/numerical
format (e.g. FY2) or the ‘popular’ alternative format (e.g. Fyb).
For clarity, it is often advisable when using the more tradi-
tional terminology to include the ISBT terminology in paren-
theses, for example Ana (GE7).
All members of the Committee, listed in Appendix I, are
prepared to handle requests for advice or assistance in any
aspect of an investigation or to direct them to the most appro-
priate authority. The Chair of the Committee would be happy
to receive any comments or criticisms of the terminology
and would raise them at a Committee meeting. Membership
of the Committee is open to colleagues who are considered





previous symbol Current no. Obsolete no.
Symbol or 
previous symbol Current no.
001005 H 018001 700010 Bpa 010010
003002 P 209001 700011 Or 002031
003003 Pk 209002 700012 Gf Obsolete
004013 RhA Obsolete 700013 Wu 010009
004014 RhB Obsolete 700014 Jna 010017
004015 RhC Obsolete 700015 Rd 013004
004016 RhD Obsolete 700016 Heibel Obsolete
004024 ET Obsolete 700020 Ana 020007
004025 LW Obsolete, see system 16 700022 Moa 010011
004038 Duclos 901013 700023 Hey Obsolete
005010 Singleton Obsolete 700024 Rla (= Lsa) 020006
005015 Anton 901009 700025 Ina 023001
006008 Kw Obsolete 700026 Fra 010020
006009 KL Obsolete 700027 Rba 010006
006015 Kx 019001 700029 Vga 010013
016001 LW1 phenotype Obsolete 700030 Wd
a 010005
016002 LW2 phenotype Obsolete 700031 Dh
a 020008
016003 LW3 phenotype Obsolete 700032 POLL Obsolete
016004 LW4 phenotype Obsolete 700033 Os
a 002038
020001 Ge1 Obsolete 700034 Hga 010012
Collection 201 GE System 020 700035 Tcb 021003
Collection 202 CROMER System 021 700036 Tcc 021004
Collection 203 IN System 023 700037 NFLD 010016
Collection 204 AU 005018 & 005019 700038 Hov (= Wu) 700013
205003 Yka 022005 700041 SW1 010021
205004 Kna 022001 700042 WES (WESa) 021008
205005 Knb 022002 700046 BOW 010015
205006 McCa 022003 700048 FPTT 004050
205007 Sla 022004 700051 ELO 010008
Collection 206 GY 014003 & 014004 700053 LOCR 004055
207001 I 027001 700055 WARR 010007
Collection 211 WR 010003 & 010004 901004 Joa 014005
209001 P 028001 901006 Oka 024001
700001 Wra 010003 901007 JMH 026001
700004 Swa 010013 901010 Wrb 010004
700007 Lsa 020006 901011 MER2 025001
700008 Tra 010019 901001 Vel 211001
700009 Wb 020005 901015 ABTI 211002
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